Dr. Reddy's Q4 Review - India Drives Growth, U.S. Remains Muted: Prabhudas Lilladher

Dr. Reddys Laboratories' R&D facility (image: Company website).

Dr. Reddy's Q4 Review - India Drives Growth, U.S. Remains Muted: Prabhudas Lilladher

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Prabhudas Lilladher Report

We marginally reduce our estimate by 1-2% for FY22E-23E, due to delay in launch of key molecules (gCopaxone, gVascepa and gNuvaring) along with increased overhead costs, higher freight costs and key clinical trials.

Dr. Reddys Laboratories Ltd. recently received another complete response letter for gCopaxone, which would delay the launch by four to six months, while new generic launches in gVescepa (by Hikma) and Nuvaring (by Teva) would further increase competitive intensity.

We expect the company to launch gCopaxone now in Q4 FY22E (versus earlier expectation of H1 FY22E), while price erosion in gNuvaring would be much steeper.

Click on the attachment to read the full report:

Prabhudas Lilladher Dr. Reddys Q4FY21 Result Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.